biologic

Antivenin (Latrodectus mactans)

Loss of exclusivityloss of exclusivity
CompanyMerck Sharp & Dohme LLC

Drug detail

Active ingredientAntivenin (Latrodectus mactans)
StrengthNLT6000U
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Antivenin (Latrodectus mactans) patent cliff — loss of exclusivity — | CliffBio